Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis

• Main Authors: Junying Wang (Author), Jeffery White (Author), Kenneth J. Sansone (Author), Lynda Spelman (Author), Rodney Sinclair (Author), Xin Yang (Author), Wubin Pan (Author), Zheng Wei (Author)
• Format: Book
• Published: Wiley, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human IgG4 kappa monoclonal antibody, blocks IL‐4Rα‐mediated signal transduction. We performed two phase I, randomized, double‐bli...